Genetics

ERS Monograph

Volumn 2016, Issue 9781849840682, 2016, Pages 16-34

  Borie, Raphael ^a   Kannengiesser, Caroline ^a,b   Nathan, Nadia ^c,d   Crestani, Bruno ^a,b  

^a BICHAT HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c ARMAND TROUSSEAU HOSPITAL   (France)

^d Assistance publique Hôpitaux de Paris   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85018306713     PISSN: 2312508X     EISSN: 23125098     Source Type: Journal    
DOI: 10.1183/2312508X.10004715     Document Type: Article

References (115)

1. Steele MP, Speer MC, Loyd JE, et al. Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med 2005; 172: 1146–1152.
2. Castaldo G, Polizzi A, Tomaiuolo R, et al. Comprehensive cystic fibrosis mutation epidemiology and haplotype characterization in a southern Italian population. Ann Hum Genet 2005; 69: 15–24.
3. Marshall RP, Puddicombe A, Cookson WO, et al. Adult familial cryptogenic fibrosing alveolitis in the United Kingdom. Thorax 2000; 55: 143–146.
4. Hodgson U, Laitinen T, Tukiainen P. Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis: evidence of founder effect among multiplex families in Finland. Thorax 2002; 57: 338–342.
5. Loyd JE. Pulmonary fibrosis in families. Am J Respir Cell Mol Biol 2003; 29: Suppl., S47–S50.
6. Garcia-Sancho C, Buendia-Roldan I, Fernandez-Plata MR, et al. Familial pulmonary fibrosis is the strongest risk factor for idiopathic pulmonary fibrosis. Respir Med 2011; 105: 1902–1907.
7. Scholand MB, Coon H, Wolff R, et al. Use of a genealogical database demonstrates heritability of pulmonary fibrosis. Lung 2013; 191: 475–481.
8. Okamoto T, Miyazaki Y, Tomita M, et al. A familial history of pulmonary fibrosis in patients with chronic hypersensitivity pneumonitis. Respiration 2013; 85: 384–390.
9. Lee HL, Ryu JH, Wittmer MH, et al. Familial idiopathic pulmonary fibrosis: clinical features and outcome. Chest 2005; 127: 2034–2041.
10. Lee HY, Seo JB, Steele MP, et al. High-resolution CT scan findings in familial interstitial pneumonia do not conform to those of idiopathic interstitial pneumonia. Chest 2012; 142: 1577–1583.
11. Leslie KO, Cool CD, Sporn TA, et al. Familial idiopathic interstitial pneumonia: histopathology and survival in 30 patients. Arch Pathol Lab Med 2012; 136: 1366–1376.
12. Fernandez BA, Fox G, Bhatia R, et al. A Newfoundland cohort of familial and sporadic idiopathic pulmonary fibrosis patients: clinical and genetic features. Respir Res 2012; 13: 64.
13. Ravaglia C, Tomassetti S, Gurioli C, et al. Features and outcome of familial idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31: 28–36.
14. Diaz de Leon A, Cronkhite JT, Katzenstein AL, et al. Telomere lengths, pulmonary fibrosis and telomerase (TERT) mutations. PLoS One 2010; 5: e10680.
15. Peljto AL, Zhang Y, Fingerlin TE, et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA 2013; 309: 2232–2239.
16. Oldham JM, Ma SF, Martinez FJ, et al. TOLLIP, MUC5B and the response to N-acetylcysteine among individuals with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2015; 192: 1475–1482.
17. Kropski JA, Pritchett JM, Zoz DF, et al. Extensive phenotyping of individuals at-risk for familial interstitial pneumonia reveals clues to the pathogenesis of interstitial lung disease. Am J Respir Crit Care Med 2014; 191: 417–426.
18. Rosas IO, Ren P, Avila NA, et al. Early interstitial lung disease in familial pulmonary fibrosis. Am J Respir Crit Care Med 2007; 176: 698–705.
19. Calado RT, Young NS. Telomere diseases. N Engl J Med 2009; 361: 2353–2365.
20. Townsley DM, Dumitriu B, Young NS. Bone marrow failure and the telomeropathies. Blood 2014; 124: 2775–2783.
21. Alder JK, Parry EM, Yegnasubramanian S, et al. Telomere phenotypes in females with heterozygous mutations in the dyskeratosis congenita 1 (DKC1) gene. Hum Mutat 2013; 34: 1481–1485.
22. Fukuhara A, Tanino Y, Ishii T, et al. Pulmonary fibrosis in dyskeratosis congenita with TINF2 gene mutation. Eur Respir J 2013; 42: 1757–1759.
23. Alder JK, Stanley SE, Wagner CL, et al. Exome sequencing identifies mutant TINF2 in a family with pulmonary fibrosis. Chest 2015; 147: 1361–1368.
24. Kannengiesser C, Borie R, Revy P. Pulmonary fibrosis associated with TINF2 gene mutation: is somatic reversion required? Eur Respir J 2014; 44: 269–270.
25. Stuart BD, Choi J, Zaidi S, et al. Exome sequencing links mutations in PARN and RTEL1 with familial pulmonary fibrosis and telomere shortening. Nat Genet 2015; 47: 512–517.
26. Cogan JD, Kropski JA, Zhao M, et al. Rare variants in RTEL1 are associated with familial interstitial pneumonia. Am J Respir Crit Care Med 2015; 191: 646–655.
27. Kannengiesser C, Borie R, Menard C, et al. Heterozygous RTEL1 mutations are associated with familial pulmonary fibrosis. Eur Respir J 2015; 46: 474–485.
28. Nunes H, Monnet I, Kannengiesser C, et al. Is telomeropathy the explanation for combined pulmonary fibrosis and emphysema syndrome?: report of a family with TERT mutation. Am J Respir Crit Care Med 2014; 189: 753–754.
29. Stanley SE, Chen JJ, Podlevsky JD, et al. Telomerase mutations in smokers with severe emphysema. J Clin Invest 2015; 125: 563–570.
30. Gorgy AI, Jonassaint NL, Stanley SE, et al. Hepatopulmonary syndrome is a frequent cause of dyspnea in the short telomere disorders. Chest 2015; 148: 1019–1026.
31. El-Chemaly S, Ziegler SG, Calado RT, et al. Natural history of pulmonary fibrosis in two subjects with the same telomerase mutation. Chest 2011; 139: 1203–1209.
32. Cottin V, Crestani B, Valeyre D, et al. [French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis. From the National Reference and the Competence Centers for Rare Diseases and the Societe de Pneumologie de Langue Francaise]. Rev Mal Respir 2013; 30: 879–902.
33. Silhan LL, Shah PD, Chambers DC, et al. Lung transplantation in telomerase mutation carriers with pulmonary fibrosis. Eur Respir J 2014; 44: 178–187.
34. Borie R, Kannengiesser C, Hirschi S, et al. Severe hematologic complications after lung transplantation in patients with telomerase complex mutations. J Heart Lung Transplant 2015; 34: 538–546.
35. Tokman S, Singer JP, Devine MS, et al. Clinical outcomes of lung transplant recipients with telomerase mutations. J Heart Lung Transplant 2015; 34: 1318–1324.
36. George G, Rosas IO, Cui Y, et al. Short telomeres, telomeropathy, and subclinical extrapulmonary organ damage in patients with interstitial lung disease. Chest 2015; 147: 1549–1557.
37. Langston AA, Sanders JE, Deeg HJ, et al. Allogeneic marrow transplantation for aplastic anaemia associated with dyskeratosis congenita. Br J Haematol 1996; 92: 758–765.
38. Diaz de Leon A, Cronkhite JT, Yilmaz C, et al. Subclinical lung disease, macrocytosis, and premature graying in kindreds with telomerase (TERT) mutations. Chest 2011; 140: 753–763.
39. Ball SE, Gibson FM, Rizzo S, et al. Progressive telomere shortening in aplastic anemia. Blood 1998; 91: 3582–3592.
40. Yamaguchi H, Baerlocher GM, Lansdorp PM, et al. Mutations of the human telomerase RNA gene (TERC) in aplastic anemia and myelodysplastic syndrome. Blood 2003; 102: 916–918.
41. Yamaguchi H, Calado RT, Ly H, et al. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med 2005; 352: 1413–1424.
42. Parry EM, Alder JK, Qi X, et al. Syndrome complex of bone marrow failure and pulmonary fibrosis predicts germline defects in telomerase. Blood 2011; 117: 5607–5611.
43. Tabeze L, Borie R, Cottin V, et al. Prévalence de mutations identifiées dans les suspicions de formes génétiques de fibroses. Rev Mal Respir 2015; 32: A19.
44. Calado RT, Brudno J, Mehta P, et al. Constitutional telomerase mutations are genetic risk factors for cirrhosis. Hepatology 2011; 53: 1600–1607.
45. Calado RT, Regal JA, Kleiner DE, et al. A spectrum of severe familial liver disorders associate with telomerase mutations. PLoS One 2009; 4: e7926.
46. Hartmann D, Srivastava U, Thaler M, et al. Telomerase gene mutations are associated with cirrhosis formation. Hepatology 2011; 53: 1608–1617.
47. Armanios M, Price C. Telomeres and disease: an overview. Mutat Res 2012; 730: 1–2.
48. Dokal I. Dyskeratosis congenita. Hematology Am Soc Hematol Educ Program 2011; 2011: 480–486.
49. Mialou V, Leblanc T, Peffault de Latour R, et al. [Dyskeratosis congenita: an update]. Arch Pediatr 2013; 20: 299–306.
50. Cronkhite JT, Xing C, Raghu G, et al. Telomere shortening in familial and sporadic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 178: 729–737.
51. Haque S, Rakieh C, Marriage F, et al. Shortened telomere length in patients with systemic lupus erythematosus. Arthritis Rheum 2013; 65: 1319–1323.
52. Hou L, Andreotti G, Baccarelli AA, et al. Lifetime pesticide use and telomere shortening among male pesticide applicators in the Agricultural Health Study. Environ Health Perspect 2013; 121: 919–924.
53. Alder JK, Guo N, Kembou F, et al. Telomere length is a determinant of emphysema susceptibility. Am J Respir Crit Care Med 2011; 184: 904–912.
54. Touzot F, Gaillard L, Vasquez N, et al. Heterogeneous telomere defects in patients with severe forms of dyskeratosis congenita. J Allergy Clin Immunol 2012; 129: 473–482.
55. Snetselaar R, van Moorsel CH, Kazemier KM, et al. Telomere length in interstitial lung diseases. Chest 2015; 148: 1011–1018.
56. Savale L, Chaouat A, Bastuji-Garin S, et al. Shortened telomeres in circulating leukocytes of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 179: 566–571.
57. Alder JK, Cogan JD, Brown AF, et al. Ancestral mutation in telomerase causes defects in repeat addition processivity and manifests as familial pulmonary fibrosis. PLoS Genet 2011; 7: e1001352.
58. Gansner JM, Rosas IO, Ebert BL. Pulmonary fibrosis, bone marrow failure, and telomerase mutation. N Engl J Med 2012; 366: 1551–1553.
59. Alder JK, Chen JJ, Lancaster L, et al. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc Natl Acad Sci U S A 2008; 105: 13051–13056.
60. Collopy LC, Walne AJ, Cardoso S, et al. Triallelic and epigenetic-like inheritance in human disorders of telomerase. Blood 2015; 126: 176–184.
61. Uringa EJ, Lisaingo K, Pickett HA, et al. RTEL1 contributes to DNA replication and repair and telomere maintenance. Mol Biol Cell 2012; 23: 2782–2792.
62. Tummala H, Walne A, Collopy L, et al. Poly(A)-specific ribonuclease deficiency impacts telomere biology and causes dyskeratosis congenita. J Clin Invest 2015; 125: 2151–2160.
63. Whitsett JA, Wert SE, Weaver TE. Alveolar surfactant homeostasis and the pathogenesis of pulmonary disease. Annu Rev Med 2010; 61: 105–119.
64. Flamein F, Riffault L, Muselet-Charlier C, et al. Molecular and cellular characteristics of ABCA3 mutations associated with diffuse parenchymal lung diseases in children. Hum Mol Genet 2012; 21: 765–775.
65. Nogee LM, Dunbar AE III, Wert SE, et al. A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med 2001; 344: 573–579.
66. Thomas AQ, Lane K, Phillips J III, et al. Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. Am J Respir Crit Care Med 2002; 165: 1322–1328.
67. Lawson WE, Crossno PF, Polosukhin VV, et al. Endoplasmic reticulum stress in alveolar epithelial cells is prominent in IPF: association with altered surfactant protein processing and herpesvirus infection. Am J Physiol Lung Cell Mol Physiol 2008; 294: L1119–L1126.
68. Mulugeta S, Nguyen V, Russo SJ, et al. A surfactant protein C precursor protein BRICHOS domain mutation causes endoplasmic reticulum stress, proteasome dysfunction, and caspase 3 activation. Am J Respir Cell Mol Biol 2005; 32: 521–530.
69. Brasch F, Griese M, Tredano M, et al. Interstitial lung disease in a baby with a de novo mutation in the SFTPC gene. Eur Respir J 2004; 24: 30–39.
70. van Moorsel CH, van Oosterhout MF, Barlo NP, et al. Surfactant protein C mutations are the basis of a significant portion of adult familial pulmonary fibrosis in a Dutch cohort. Am J Respir Crit Care Med 2010; 182: 1419–1425.
71. Mechri M, Epaud R, Emond S, et al. Surfactant protein C gene (SFTPC) mutation-associated lung disease: high-resolution computed tomography (HRCT) findings and its relation to histological analysis. Pediatr Pulmonol 2010; 45: 1021–1029.
72. Ono S, Tanaka T, Ishida M, et al. Surfactant protein C G100S mutation causes familial pulmonary fibrosis in Japanese kindred. Eur Respir J 2011; 38: 861–869.
73. Cottin V, Reix P, Khouatra C, et al. Combined pulmonary fibrosis and emphysema syndrome associated with familial SFTPC mutation. Thorax 2011; 66: 918–919.
74. Thouvenin G, Abou Taam R, Flamein F, et al. Characteristics of disorders associated with genetic mutations of surfactant protein C. Arch Dis Child 2010; 95: 449–454.
75. Kroner C, Reu S, Teusch V, et al. Genotype alone does not predict the clinical course of SFTPC deficiency in paediatric patients. Eur Respir J 2015; 46: 197–206.
76. Wambach JA, Casey AM, Fishman MP, et al. Genotype–phenotype correlations for infants and children with ABCA3 deficiency. Am J Respir Crit Care Med 2014; 189: 1538–1543.
77. Wang Y, Kuan PJ, Xing C, et al. Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. Am J Hum Genet 2009; 84: 52–59.
78. Coghlan MA, Shifren A, Huang HJ, et al. Sequencing of idiopathic pulmonary fibrosis-related genes reveals independent single gene associations. BMJ Open Respir Res 2014; 1: e000057.
79. Horton CJ, Mitui M, Leos NK, et al. Long-range PCR based sequencing of the highly homologous genes, SFTPA1 and SFTPA2. Mol Cell Probes 2013; 27: 115–117.
80. Thouvenin G, Nathan N, Epaud R, et al. Diffuse parenchymal lung disease caused by surfactant deficiency: dramatic improvement by azithromycin. BMJ Case Rep 2013; 2013.
81. Epaud R, Delestrain C, Louha M, et al. Combined pulmonary fibrosis and emphysema syndrome associated with ABCA3 mutations. Eur Respir J 2014; 43: 638–641.
82. Campo I, Zorzetto M, Mariani F, et al. A large kindred of pulmonary fibrosis associated with a novel ABCA3 gene variant. Respir Res 2014; 15: 43.
83. Huizing M, Helip-Wooley A, Westbroek W, et al. Disorders of lysosome-related organelle biogenesis: clinical and molecular genetics. Annu Rev Genomics Hum Genet 2008; 9: 359–386.
84. Santiago Borrero PJ, Rodriguez-Perez Y, Renta JY, et al. Genetic testing for oculocutaneous albinism type 1 and 2 and Hermansky–Pudlak syndrome type 1 and 3 mutations in Puerto Rico. J Invest Dermatol 2006; 126: 85–90.
85. Gahl WA, Brantly M, Kaiser-Kupfer MI, et al. Genetic defects and clinical characteristics of patients with a form of oculocutaneous albinism (Hermansky–Pudlak syndrome). N Engl J Med 1998; 338: 1258–1264.
86. Pierson DM, Ionescu D, Qing G, et al. Pulmonary fibrosis in Hermansky–Pudlak syndrome. A case report and review. Respiration 2006; 73: 382–395.
87. Gahl WA, Brantly M, Troendle J, et al. Effect of pirfenidone on the pulmonary fibrosis of Hermansky–Pudlak syndrome. Mol Genet Metab 2002; 76: 234–242.
88. O’Brien K, Troendle J, Gochuico BR, et al. Pirfenidone for the treatment of Hermansky–Pudlak syndrome pulmonary fibrosis. Mol Genet Metab 2011; 103: 128–134.
89. Riccardi VM. Von Recklinghausen neurofibromatosis. N Engl J Med 1981; 305: 1617–1627.
90. Zamora AC, Collard HR, Wolters PJ, et al. Neurofibromatosis-associated lung disease: a case series and literature review. Eur Respir J 2007; 29: 210–214.
91. Ryu JH, Parambil JG, McGrann PS, et al. Lack of evidence for an association between neurofibromatosis and pulmonary fibrosis. Chest 2005; 128: 2381–2386.
92. Hamvas A, Deterding RR, Wert SE, et al. Heterogeneous pulmonary phenotypes associated with mutations in the thyroid transcription factor gene NKX2-1. Chest 2013; 144: 794–804.
93. Liu Y, Jesus AA, Marrero B, et al. Activated STING in a vascular and pulmonary syndrome. N Engl J Med 2014; 371: 507–518.
94. Jeremiah N, Neven B, Gentili M, et al. Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations. J Clin Invest 2014; 124: 5516–5520.
95. Watkin LB, Jessen B, Wiszniewski W, et al. COPA mutations impair ER–Golgi transport and cause hereditary autoimmune-mediated lung disease and arthritis. Nat Genet 2015; 47: 654–660.
96. Mercier S, Kury S, Shaboodien G, et al. Mutations in FAM111B cause hereditary fibrosing poikiloderma with tendon contracture, myopathy, and pulmonary fibrosis. Am J Hum Genet 2013; 93: 1100–1107.
97. Horimasu Y, Ohshimo S, Bonella F, et al. MUC5B promoter polymorphism in Japanese patients with idiopathic pulmonary fibrosis. Respirology 2015; 20: 439–444.
98. Borie R, Crestani B, Dieude P, et al. The MUC5B variant is associated with idiopathic pulmonary fibrosis but not with systemic sclerosis interstitial lung disease in the European Caucasian population. PLoS One 2013; 8: e70621.
99. Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med 2011; 364: 1503–1512.
100. Plantier L, Crestani B, Wert SE, et al. Ectopic respiratory epithelial cell differentiation in bronchiolised distal airspaces in idiopathic pulmonary fibrosis. Thorax 2011; 66: 651–657.
101. Roy MG, Livraghi-Butrico A, Fletcher AA, et al. Muc5b is required for airway defence. Nature 2014; 505: 412–416.
102. Peljto AL, Selman M, Kim DS, et al. The MUC5B promoter polymorphism is associated with idiopathic pulmonary fibrosis in a Mexican cohort but is rare among Asian ancestries. Chest 2015; 147: 460–464.
103. Wang C, Zhuang Y, Guo W, et al. Mucin 5B promoter polymorphism is associated with susceptibility to interstitial lung diseases in Chinese males. PLoS One 2014; 9: e104919.
104. Stock CJ, Sato H, Fonseca C, et al. Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. Thorax 2013; 68: 436–441.
105. Chung JH, Chawla A, Peljto AL, et al. CT scan findings of probable usual interstitial pneumonitis have a high predictive value for histologic usual interstitial pneumonitis. Chest 2015; 147: 450–459.
106. Korthagen NM, van Moorsel CH, Kazemier KM, et al. IL1RN genetic variations and risk of IPF: a meta-analysis and mRNA expression study. Immunogenetics 2012; 64: 371–377.
107. Bournazos S, Grinfeld J, Alexander KM, et al. Association of FcγRIIa R131H polymorphism with idiopathic pulmonary fibrosis severity and progression. BMC Pulm Med 2010; 10: 51.
108. Korthagen NM, van Moorsel CH, Barlo NP, et al. Association between variations in cell cycle genes and idiopathic pulmonary fibrosis. PLoS One 2012; 7: e30442.
109. Fingerlin TE, Murphy E, Zhang W, et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet 2013; 45: 613–620.
110. Codd V, Nelson CP, Albrecht E, et al. Identification of seven loci affecting mean telomere length and their association with disease. Nat Genet 2013; 45: 422–427.
111. Noth I, Zhang Y, Ma S, et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir Med 2013; 1: 309–317.
112. Helling BA, Yang IV. Epigenetics in lung fibrosis: from pathobiology to treatment perspective. Curr Opin Pulm Med 2015; 21: 454–462.
113. Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. Nature 2009; 461: 747–753.
114. McCarthy MI, Abecasis GR, Cardon LR, et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet 2008; 9: 356–369.
115. Montani D, Coulet F, Girerd B, et al. Pulmonary hypertension in patients with neurofibromatosis type I. Medicine (Baltimore) 2011; 90: 201–211.